Clinical trials: Lipodystrophy, Partial
Generalized Lipodystrophy
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD).
- Trial name
- LAGO (NCT07220785)
- Testing
- Mibavademab
- Where
- 9 sites in United States, Brazil and 1 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Lipodystrophy, Dunnigan Syndrome
Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects
Few data and small numbers affect the inflammatory profile of Dunnigan patients. The levels of certain pro-inflammatory biomarkers would be found higher in these subjects compared to control individuals.
- Trial name
- LIPOKINES (NCT06107439)
- Testing
- Bood and urine sampling
- Where
- Reunion
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial
Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology.
- Conditions
- Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial, Turner Syndrome
- Trial name
- LIPTURN (NCT07799012)
- Where
- France
- Volunteers
- 1,416 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Insulin Receptor Mutation, Partial Lipodystrophy
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
Background: Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant.
- Trial name
- NCT05470504
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Polycystic Ovary Syndrome, Familial Partial Lipodystrophy
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS)
Diagnostic case-control study (1 case for 2 controls). Inclusion of patients with severe insulin resistance syndrome of genetic origin, then inclusion of controls: patients examined for PCOS in day hospital with matching age (+/…
- Conditions
- Polycystic Ovary Syndrome, Familial Partial Lipodystrophy, LMNA (LaMin Nuclear A) Related Disorders
- Trial name
- ANDROLIPO (NCT07412028)
- Testing
- Genetic analysis, Biological analysis, imaging test
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Generalised Lipodystrophy, Partial Lipodystrophy
MEASuRE: Metreleptin Effectiveness And Safety Registry
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
- Trial name
- MEASuRE (NCT02325674)
- Testing
- Metreleptin
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Familial Partial Lipodystrophy
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
- Trial name
- NCT06679270
- Testing
- Metreleptin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Partial Lipodystrophy
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
- Trial name
- METRE-PL (NCT05164341)
- Testing
- metreleptin
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 69 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome
Metabolic Phenotyping in vEDS
This research study will investigate whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way their body stores and uses fat (adipose tissue).
- Conditions
- Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome, Vascular EDS (vEDS)
- Trial name
- MPEDS (NCT07516496)
- Testing
- No intervention, observational
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Familial Partial Lipodystrophy Type 2
Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2
Familial partial lipodystrophic syndromes are characterized by an increase in visceral adipose tissue and an atrophy of subcutaneous adipose tissue.
- Trial name
- LIPOCORT (NCT04845165)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Lille
Lipodystrophy Acquired, Lipodystrophy Congenital
Registry for Patients With Lipodystrophy
Given the lack of knowledge on lipodystrophies, the medical and social responsibility for the persons affected by it calls for the monitoring of the progression over long periods of time.
- Trial name
- ECLip Registry (NCT03553420)
- Where
- 28 sites in Austria, France and 14 more
- Volunteers
- 5,000 people
- Sponsor
- University of Ulm
Familial Partial Lipodystrophy, Metabolic Abnormalities
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin <8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL The primary objectives will be…
- Trial name
- LEAP (NCT05088460)
- Testing
- REGN4461
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Lipodystrophy, Partial
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of…
- Trial name
- TILT-2024 (NCT07091734)
- Testing
- Tirzepatide, Usual care medications
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan
High Cholesterol, Lipodystrophy, Familial Partial
The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.
The goal of this retrospective study is to see whether patients with familial partial type 2 lipodystrophy, who are at high cardiovascular risk present a higher volume of visceral epicardial adipose tissue than other patients…
- Conditions
- High Cholesterol, Lipodystrophy, Familial Partial, Diabetes
- Trial name
- EPICAC-RUN (NCT07090629)
- Testing
- Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring
- Where
- Reunion
- Volunteers
- 126 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Partial Lipodystrophy
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
- Trial name
- NCT06484868
- Testing
- Metreleptin
- Where
- 12 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Amryt Pharma
Lipodystrophy, Diabetes
Low Energy Diet and Familial Partial Lipodystrophy
To evaluate the therapeutic efficacy and metabolic impact of a low energy diet (LED) in people with familial partial lipodystrophy and diabetes.
- Conditions
- Lipodystrophy, Diabetes, Diet Modification
- Trial name
- NCT03900286
- Testing
- Total Dietary Replacement
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Familial Partial Lipodystrophy
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Lipodystrophies are rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications.
- Trial name
- NCT02430077
- Testing
- Obeticholic Acid
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Abhimanyu Garg
Hypoleptinemia, Generalized Lipodystrophy
Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Lipodystrophies represent a therapeutic challenge with regards to insulin resistance, hypertriglyceridemia and fatty liver which often is coupled with significant adipose tissue loss.
- Conditions
- Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
- Trial name
- NCT00896298
- Testing
- Leptin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Lipodystrophy, Dunnigan Syndrome
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
The objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation.
- Trial name
- IRAP-DUN 2 (NCT05424913)
- Testing
- research-specific blood sample
- Where
- Reunion
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion